Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891910905> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W2891910905 endingPage "4540" @default.
- W2891910905 startingPage "4540" @default.
- W2891910905 abstract "4540 Background: Patients w/ locally advanced or metastatic urothelial carcinoma (UCC) have a poor prognosis. Prior to atezolizumab’s approval, there were no approved treatments (txs) for pts who progressed after chemotherapy. Even w/ immune checkpoint inhibitors, most pts require additional txs. FGFR3 is frequently overexpressed in UCC and 15-20% of pts w/ advanced disease have tumors w/ FGFR3 gene mutations or fusions. B-701 (formerly R3Mab) is a fully human monoclonal antibody against FGFR3 that blocks activation of the wildtype and genetically activated receptor. NCT02401542 is a phase (ph) 1b/2 study designed to evaluate the safety and efficacy of B-701 plus docetaxel (D) in advanced UCC pts. Methods: The study has a lead-in (n=20 pts) and a randomized ph (n=201). Eligible pts: Stage IV UCC, relapsed/refractory to 1 or 2 prior chemotherapy regimens not including taxanes with ECOG 0-1. Txs: B-701 at 25 mg/kg q3w (+ loading dose on C1D8) and D at 75 mg/m 2 q3w. Efficacy assessed by RECIST 1.1. Primary obj: PFS and safety. Secondary obj: overall response rate (ORR); duration of response (DOR); disease control rate (DCR); overall survival (OS). Exploratory obj: association of FGFR3 status w/ efficacy and AEs. Results: As of 20 Jan 2017, 19 pts enrolled to lead-in ph w/median age 66 yrs, ECOG 1 58%, Hgb <10 gm/dL 5%, liver mets 26% and ≥ 2 prior regimens 63%. 17 evaluable for PFS/ORR. 5 pts w/ FGFR3 mut or TACC3-fus. Gr ≥3 AEs occurring in ≥2 pts: decreased neutrophils (26.3%), neutropenia (10.5%), decreased WBCs (10.5%). 2 pts had D dose reductions and 1 pt discontinued tx due to AE (disseminated intravascular coagulation). Conclusions: Preliminary results show that B-701 combines safely and effectively with D in UCC, with the combination being well tolerated and showing promising ORR and PFS in pts w/ FGFR3 mut/fus. The protocol has been amended to add Cohorts 2 (B-701+D) and 3 (B-701) (n=20 pts/cohort) for pts w/ FGFR3 mut/fus+ tumors only. Clinical trial information: NCT02401542. [Table: see text]" @default.
- W2891910905 created "2018-09-27" @default.
- W2891910905 creator A5021900842 @default.
- W2891910905 creator A5031968057 @default.
- W2891910905 creator A5034354367 @default.
- W2891910905 creator A5036657478 @default.
- W2891910905 creator A5041033274 @default.
- W2891910905 creator A5063056787 @default.
- W2891910905 creator A5074756323 @default.
- W2891910905 creator A5076370404 @default.
- W2891910905 creator A5083920381 @default.
- W2891910905 date "2017-05-20" @default.
- W2891910905 modified "2023-09-27" @default.
- W2891910905 title "Safety and efficacy of docetaxel + b-701, a selective inhibitor of FGFR3, in subjects with advanced or metastatic urothelial carcinoma." @default.
- W2891910905 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.4540" @default.
- W2891910905 hasPublicationYear "2017" @default.
- W2891910905 type Work @default.
- W2891910905 sameAs 2891910905 @default.
- W2891910905 citedByCount "8" @default.
- W2891910905 countsByYear W28919109052018 @default.
- W2891910905 countsByYear W28919109052019 @default.
- W2891910905 countsByYear W28919109052020 @default.
- W2891910905 countsByYear W28919109052021 @default.
- W2891910905 crossrefType "journal-article" @default.
- W2891910905 hasAuthorship W2891910905A5021900842 @default.
- W2891910905 hasAuthorship W2891910905A5031968057 @default.
- W2891910905 hasAuthorship W2891910905A5034354367 @default.
- W2891910905 hasAuthorship W2891910905A5036657478 @default.
- W2891910905 hasAuthorship W2891910905A5041033274 @default.
- W2891910905 hasAuthorship W2891910905A5063056787 @default.
- W2891910905 hasAuthorship W2891910905A5074756323 @default.
- W2891910905 hasAuthorship W2891910905A5076370404 @default.
- W2891910905 hasAuthorship W2891910905A5083920381 @default.
- W2891910905 hasConcept C121332964 @default.
- W2891910905 hasConcept C121608353 @default.
- W2891910905 hasConcept C126322002 @default.
- W2891910905 hasConcept C126894567 @default.
- W2891910905 hasConcept C142424586 @default.
- W2891910905 hasConcept C143998085 @default.
- W2891910905 hasConcept C2776694085 @default.
- W2891910905 hasConcept C2779984678 @default.
- W2891910905 hasConcept C2780352672 @default.
- W2891910905 hasConcept C2780739268 @default.
- W2891910905 hasConcept C2781190966 @default.
- W2891910905 hasConcept C2911057145 @default.
- W2891910905 hasConcept C3019882237 @default.
- W2891910905 hasConcept C31760486 @default.
- W2891910905 hasConcept C71924100 @default.
- W2891910905 hasConcept C87355193 @default.
- W2891910905 hasConcept C90924648 @default.
- W2891910905 hasConceptScore W2891910905C121332964 @default.
- W2891910905 hasConceptScore W2891910905C121608353 @default.
- W2891910905 hasConceptScore W2891910905C126322002 @default.
- W2891910905 hasConceptScore W2891910905C126894567 @default.
- W2891910905 hasConceptScore W2891910905C142424586 @default.
- W2891910905 hasConceptScore W2891910905C143998085 @default.
- W2891910905 hasConceptScore W2891910905C2776694085 @default.
- W2891910905 hasConceptScore W2891910905C2779984678 @default.
- W2891910905 hasConceptScore W2891910905C2780352672 @default.
- W2891910905 hasConceptScore W2891910905C2780739268 @default.
- W2891910905 hasConceptScore W2891910905C2781190966 @default.
- W2891910905 hasConceptScore W2891910905C2911057145 @default.
- W2891910905 hasConceptScore W2891910905C3019882237 @default.
- W2891910905 hasConceptScore W2891910905C31760486 @default.
- W2891910905 hasConceptScore W2891910905C71924100 @default.
- W2891910905 hasConceptScore W2891910905C87355193 @default.
- W2891910905 hasConceptScore W2891910905C90924648 @default.
- W2891910905 hasIssue "15_suppl" @default.
- W2891910905 hasLocation W28919109051 @default.
- W2891910905 hasOpenAccess W2891910905 @default.
- W2891910905 hasPrimaryLocation W28919109051 @default.
- W2891910905 hasRelatedWork W2080820783 @default.
- W2891910905 hasRelatedWork W2085307618 @default.
- W2891910905 hasRelatedWork W2087322859 @default.
- W2891910905 hasRelatedWork W2103201965 @default.
- W2891910905 hasRelatedWork W2167650070 @default.
- W2891910905 hasRelatedWork W2234542209 @default.
- W2891910905 hasRelatedWork W2261580129 @default.
- W2891910905 hasRelatedWork W2301488980 @default.
- W2891910905 hasRelatedWork W3032029751 @default.
- W2891910905 hasRelatedWork W87346260 @default.
- W2891910905 hasVolume "35" @default.
- W2891910905 isParatext "false" @default.
- W2891910905 isRetracted "false" @default.
- W2891910905 magId "2891910905" @default.
- W2891910905 workType "article" @default.